At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
AL-53817 Ophthalmic Solution, 0.1% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model
In Brief
A Phase 2 clinical trial evaluating AL-53817 Ophthalmic Solution, 0.1%, AL-78843 Ophthalmic Solution, 0.03%, and 2 other interventions for Allergic Conjunctivitis. Completed, enrolled 224 participants.
Detailed Summary
The purpose of this study is to evaluate two investigational ophthalmic solutions for reduction in ocular redness in subjects with allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartApr 2014
Primary CompletionJul 2014
TodayJul 2026
First PostedMar 6, 2014
Enrollment StartApr 1, 2014
Primary CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.3 years ago
Interventions
AL-53817 Ophthalmic Solution, 0.1%drug
AL-78843 Ophthalmic Solution, 0.03%drug
Dexamethasone Ophthalmic Suspension, 0.1%drug
AL-53817 Vehicledrug
Inactive ingredients used for masking purposes